A Pilot Phase 2 Study of Albumin-bound Rapamycin Nanoparticles, ABI-009, in Patients With Metastatic, Unresectable, Low or Intermediate Grade Neuroendocrine Tumors of the Lung or Gastroenteropancreatic System

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 10 Sep 2019

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Sirolimus (Primary)
Indications Gastrointestinal cancer; Lung cancer; Neuroendocrine tumours; Pancreatic cancer
Focus Therapeutic Use

Most Recent Events

10 Sep 2019 As per the trial design presented at the 20th World Conference on Lung Cancer, currently, 3 of the planned 10 patients have been enrolled
10 Sep 2019 Trial design presented at the 20th World Conference on Lung Cancer
06 Feb 2019 Status changed from not yet recruiting to recruiting.

Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

Login with a username/password associated to an account with a valid subscription
Contact your organization’s admin about adding this content to your AdisInsight subscription
Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Welcome to AdisInsight